Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The company focuses on pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, targeting neurotransmitter pathways. Its lead product candidate, DT120 ODT, is a proprietary form of lysergide D-tartrate being developed for the treatment of adults with generalized anxiety disorder and major depressive disorder. A second lead candidate, DT402, is a proprietary form of the R-enantiomer of MDMA being developed for the treatment of adults with autism spectrum disorder. The company conducts clinical trials and research and development activities to advance these candidates through regulatory approval processes. Definium Therapeutics was formerly known as Mind Medicine (MindMed) Inc. and was incorporated in 2010.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ir.definiumtx.com
Sector Healthcare IR page ir.definiumtx.com
Tags
psychedelic therapeutics, neuropsychiatry, anxiety disorders, depression, autism spectrum disorder, clinical-stage, lysergide, mdma, brain health, DT120, MM120, DT402, MM402, DT120 ODT, R(-)-MDMA, Voyage, Panorama, Emerge, Ascend, Definium US
Press page —

Metrics

Valuation  
Market cap $ 5.21B
Market cap (USD) $ 5.21B
P/E -12.52
PEG —
P/BV 5.38
P/S —
P/OCF -27.23
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -64.1%
ROI -49.3%
ROIC -33.4%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 3.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 440.1M 302.151M 124.541M 169.993M 164.002M 81.519M
Net profit -183.793M -108.679M -95.732M -56.796M -93.036M -33.937M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 13.39 — — — — —
P/OCF -10.05 — — — — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) — — — 14.1M 21.9M 40.6M
Cash and deposits (USD) 80.1M 134M 142M 99.7M 274M 258M
Intangible assets (USD) — 6.87M 3.69M 527,000 0.00 —
Net debt (borrowings + leases - cash) (USD) — — — -85.6M -252M -217M
Cash flow detail
Operating cash flow (USD) -23.6M -45.8M -50.1M -64.4M -79.1M -132M
Change in payables (cash effect) (USD) 544,000 1.28M -2.06M 2.03M -2.13M 3.34M
Interest paid (cash effect) (USD) — — — -534,000 -2.22M -5.34M
Income taxes paid (cash effect) (USD) — — — — — 0.00
Share-based compensation (USD) 7.41M 42.7M 13.7M 15.5M 16.9M 20.1M
Income detail
Research and development expense (USD) 18.6M 34.8M 36.2M 52.1M 65.3M 118M
↳ 5y CAGR +44.6%
Total comprehensive income (USD) -33.7M -92.3M -57.2M -96M -108M -184M
Comprehensive income to owners (USD) -33.7M -92.3M -57.2M -96M -108M -184M
Reported Mar 28, 2022 Mar 28, 2022 Mar 9, 2023 Feb 28, 2024 Mar 6, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD)

Received FDA Breakthrough Therapy Designation for DT120 ODT in major depressive disorder (MDD)

On track for DT120 ODT NDA filing in first half of 2027

DT402 demonstrated positive initial results in a Phase 2a trial in adults with autism spectrum disorder (ASD); clinical study evaluating multiple dosing paradigms planned for 2027

Approximately $1.05 billion in cash, cash equivalents, and investments as of September 30, 2026

Conference call scheduled today at 4:30 p.m. EST

NEW YORK, November 9, 2026 -- Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also reported positive initial results from its Phase 2a trial of DT402 in adults with ASD, with improvements observed across several measures of socialization, communication and other functional outcomes.

October 29, 2026 4:01pm EDT Download as PDF

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended September 30, 2026, and discuss recent business highlights.

Listeners can register for the webcast via this link . Analysts wishing to participate in the question and answer session should use this link . A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

Nov 9, 2026 4:30 pm EST

Analysts wishing to participate in the question and answer session should use this link . A replay of the webcast will be available and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

WebcastAudio

©2026 Definium Therapeutics . All Rights Reserved.

Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .

Prompts

Definium Therapeutics, Inc. (ticker DFTX), listed in United States.

Company History

Date Change Detail
Jan 29, 2026 Renamed MIND MEDICINE (MINDMED) INC. → DEFINIUM THERAPEUTICS, INC.
— Former tickers MNMD

ETFs Holding Definium Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 11.81% 153,124 $ 4.499M Nov 17, 2026
NBDS 4.96% 230,060 $ 9.138M Aug 31, 2026
GSC 1.11% 77,722 $ 3.087M Aug 31, 2026
GDOC 0.75% 3,695 $ 146.765K Aug 31, 2026
MMSC 0.64% 10,633 $ 320.691K Nov 16, 2026
FMED 0.37% 4,800 $ 190.656K Aug 31, 2026
FSEG 0.35% 431 $ 20.274K Jun 30, 2026
FESM 0.30% 373,412 $ 17.565M Jun 30, 2026
CGMM 0.28% 342,075 $ 10.317M Nov 16, 2026
VFMO 0.17% 84,158 $ 3.343M Aug 31, 2026
FTKI 0.17% 1,427 $ 43.038K Nov 16, 2026
FBCG 0.06% 103,206 $ 4.492M Jul 31, 2026
MSSM 0.03% 4,566 $ 181.362K Aug 31, 2026